BR112015025413A2 - inibidores de proteína cinase - Google Patents

inibidores de proteína cinase

Info

Publication number
BR112015025413A2
BR112015025413A2 BR112015025413A BR112015025413A BR112015025413A2 BR 112015025413 A2 BR112015025413 A2 BR 112015025413A2 BR 112015025413 A BR112015025413 A BR 112015025413A BR 112015025413 A BR112015025413 A BR 112015025413A BR 112015025413 A2 BR112015025413 A2 BR 112015025413A2
Authority
BR
Brazil
Prior art keywords
protein kinase
kinase inhibitors
gffr
formula
inhibitors
Prior art date
Application number
BR112015025413A
Other languages
English (en)
Inventor
Narasingapuram Arumugam Karthikeyan
Appukuttan Prasad
Kotrabasaiah Ujjinamatada Ravi
George Shyla
Rajagopalan Srinivasan
Linnanen Tero
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of BR112015025413A2 publication Critical patent/BR112015025413A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo "inibidores de proteína cinase" um composto da fórmula (i) em que r1 a r5, a, b, z, z1 e z2 são como definido nas reivindicações, e sais farmaceuticamente aceitáveis dos mesmos são revelados. os compostos da fórmula (i) possuem utilidade como inibidores de fgfr e são úteis no tratamento de uma condição onde, se deseja inibição de fgfr cinase, como câncer.
BR112015025413A 2013-04-04 2014-04-03 inibidores de proteína cinase BR112015025413A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN382KO2013 2013-04-04
PCT/FI2014/000003 WO2014162039A1 (en) 2013-04-04 2014-04-03 Protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112015025413A2 true BR112015025413A2 (pt) 2017-07-18

Family

ID=50685938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025413A BR112015025413A2 (pt) 2013-04-04 2014-04-03 inibidores de proteína cinase

Country Status (34)

Country Link
US (1) US20160031855A1 (pt)
EP (1) EP2981533B1 (pt)
JP (1) JP6356782B2 (pt)
KR (1) KR20150138383A (pt)
CN (1) CN105073733B (pt)
AR (1) AR095781A1 (pt)
AU (1) AU2014246961B2 (pt)
BR (1) BR112015025413A2 (pt)
CA (1) CA2907855A1 (pt)
CL (1) CL2015002932A1 (pt)
CY (1) CY1120306T1 (pt)
DK (1) DK2981533T3 (pt)
EA (1) EA031076B1 (pt)
ES (1) ES2658183T3 (pt)
HK (1) HK1217198A1 (pt)
HR (1) HRP20180382T1 (pt)
HU (1) HUE036692T2 (pt)
LT (1) LT2981533T (pt)
MA (1) MA38454B1 (pt)
MX (1) MX2015013776A (pt)
MY (1) MY184528A (pt)
NO (1) NO2981533T3 (pt)
NZ (1) NZ713410A (pt)
PE (1) PE20160115A1 (pt)
PH (1) PH12015502284A1 (pt)
PL (1) PL2981533T3 (pt)
PT (1) PT2981533T (pt)
RS (1) RS56942B1 (pt)
SA (1) SA515361260B1 (pt)
SG (1) SG11201508125XA (pt)
SI (1) SI2981533T1 (pt)
TW (1) TWI628176B (pt)
UA (1) UA115176C2 (pt)
WO (1) WO2014162039A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
TWI715901B (zh) 2013-04-19 2021-01-11 美商英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN113004278B (zh) 2015-02-20 2023-07-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10487863B2 (en) * 2017-02-17 2019-11-26 Ford Global Technologies, Llc Castellated joint for improved adhesive coverage when using mechanical fixings and adhesive in one joint
RU2764655C2 (ru) 2017-03-16 2022-01-19 Цзянсу Хэнжуй Медицин Ко., Лтд. ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
KR20220020918A (ko) * 2019-06-14 2022-02-21 메드샤인 디스커버리 아이엔씨. Fgfr 및 vegfr 이중 억제제로서의 축합고리 화합물
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114072402B (zh) * 2019-07-26 2023-12-26 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的吡啶衍生物
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR102655210B1 (ko) * 2021-03-26 2024-04-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2376957A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
AU5889100A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
BRPI0413746A (pt) * 2003-08-21 2006-10-24 Osi Pharm Inc composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
CN101558068A (zh) * 2006-10-16 2009-10-14 诺瓦提斯公司 用作蛋白激酶抑制剂的苯乙酰胺类
CN101679408B (zh) * 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
WO2008078100A2 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CN102216300B (zh) * 2009-09-30 2014-10-22 贝达药业股份有限公司 作为蛋白激酶抑制剂的化合物和组合物
UA111382C2 (uk) * 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази

Also Published As

Publication number Publication date
JP6356782B2 (ja) 2018-07-11
CN105073733A (zh) 2015-11-18
HUE036692T2 (hu) 2018-07-30
WO2014162039A1 (en) 2014-10-09
AU2014246961A1 (en) 2015-10-22
RS56942B1 (sr) 2018-05-31
PH12015502284B1 (en) 2016-02-01
HK1217198A1 (zh) 2016-12-30
SI2981533T1 (en) 2018-04-30
PH12015502284A1 (en) 2016-02-01
CN105073733B (zh) 2017-06-27
AU2014246961B2 (en) 2017-09-28
PT2981533T (pt) 2018-02-27
SA515361260B1 (ar) 2017-08-27
AR095781A1 (es) 2015-11-11
JP2016515604A (ja) 2016-05-30
EA201591913A1 (ru) 2016-03-31
ES2658183T3 (es) 2018-03-08
NZ713410A (en) 2018-07-27
TWI628176B (zh) 2018-07-01
PE20160115A1 (es) 2016-03-03
CA2907855A1 (en) 2014-10-09
MY184528A (en) 2021-04-01
CL2015002932A1 (es) 2016-04-22
EP2981533B1 (en) 2017-12-06
MA38454A1 (fr) 2018-02-28
HRP20180382T1 (hr) 2018-04-06
TW201524970A (zh) 2015-07-01
EP2981533A1 (en) 2016-02-10
CY1120306T1 (el) 2019-07-10
KR20150138383A (ko) 2015-12-09
SG11201508125XA (en) 2015-10-29
DK2981533T3 (en) 2018-02-12
US20160031855A1 (en) 2016-02-04
MX2015013776A (es) 2016-02-26
LT2981533T (lt) 2018-02-26
MA38454B1 (fr) 2018-11-30
UA115176C2 (uk) 2017-09-25
EA031076B1 (ru) 2018-11-30
PL2981533T3 (pl) 2018-04-30
NO2981533T3 (pt) 2018-05-05

Similar Documents

Publication Publication Date Title
BR112015025413A2 (pt) inibidores de proteína cinase
BR112014008495A2 (pt) inibidores de proteína quinase
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
PH12016500225B1 (en) Novel quinoline-substituted compound
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
EA201492210A1 (ru) Соединения, ингибирующие активность катехол-o-метилтрансферазы
BR112015020795A2 (pt) derivados de pirazol novos
BR112018013977A2 (pt) derivados de quinolin-2-ona
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
EA201500931A1 (ru) Производные пиридин-4-ила
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
BR112015019624A2 (pt) quinazolinas como inibidores de quinase
BR112018011562A2 (pt) novos derivados de fenil
BR112015020834A2 (pt) novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)
BR112014012521A2 (pt) novos derivados de pirrolidina como inibidores de catepsina
EA201690818A1 (ru) Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов
BR112015028574A2 (pt) derivados substituídos de isoxazol
EA201590656A1 (ru) Азаиндолины
AU2016248387A8 (en) Preparation and use of kinase inhibitor
EA033106B1 (ru) Производное пуринил-n-гидроксипиримидинформамида, способы его получения и его применения
BR112016002027A2 (pt) derivados de 2-benzoilaminobenzamida como inibidores de bcl-3
BR112015018355A8 (pt) novos compostos de pirimidina condensados substituídos
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements